A Non-interventional, Multi-centric, Observational, Prospective Study to Collect the Criteria on Which Renewal of GnRH Analogue Treatment With Triptorelin (Diphereline 3.75mg or Diphereline pr 11.25mg) is Made in Patients Recently Diagnosed With Prostate Cancer Requiring Androgen Deprivation Therapy
Phase of Trial: Phase IV
Latest Information Update: 01 Feb 2018
At a glance
- Drugs Triptorelin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms CHRONOS3
- Sponsors Ipsen
- 26 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Mar 2018.
- 26 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2018.
- 30 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.